Details for New Drug Application (NDA): 220626
✉ Email this page to a colleague
NDA 220626 describes EPINEPHRINE, which is a drug marketed by Armstrong Pharms, Am Regent, Amneal, Baxter Hlthcare Corp, Bpi Labs, Fresenius Kabi Usa, Gland, Intl Medication Sys, Hospira, and Teva Pharms Usa, and is included in sixteen NDAs. It is available from seventeen suppliers. There is one patent protecting this drug. Additional details are available on the EPINEPHRINE profile page.
The generic ingredient in EPINEPHRINE is epinephrine bitartrate. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinephrine bitartrate profile page.
The generic ingredient in EPINEPHRINE is epinephrine bitartrate. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinephrine bitartrate profile page.
Summary for 220626
| Tradename: | EPINEPHRINE |
| Applicant: | Baxter Hlthcare Corp |
| Ingredient: | epinephrine |
| Patents: | 0 |
Pharmacology for NDA: 220626
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Medical Subject Heading (MeSH) Categories for 220626
Suppliers and Packaging for NDA: 220626
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EPINEPHRINE | epinephrine | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 220626 | NDA | Baxter Healthcare Corporation | 43066-801 | 43066-801-02 | 1 VIAL, MULTI-DOSE in 1 CARTON (43066-801-02) / 30 mL in 1 VIAL, MULTI-DOSE (43066-801-01) |
| EPINEPHRINE | epinephrine | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 220626 | NDA | Baxter Healthcare Corporation | 43066-803 | 43066-803-25 | 25 VIAL, SINGLE-DOSE in 1 CARTON (43066-803-25) / 1 mL in 1 VIAL, SINGLE-DOSE (43066-803-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | Strength | 1MG/ML (1MG/ML) | ||||
| Approval Date: | Mar 30, 2026 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | Strength | 30MG/30ML (1MG/ML) | ||||
| Approval Date: | Mar 30, 2026 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
